New Cancer Treatment Shows Promise for Public Access by 2027

A transformative cancer treatment developed in Wellington could be available to patients in New Zealand by 2027, pending regulatory approval. This innovative therapy, known as CAR T-cell therapy, has shown remarkable success in trials, with patients facing terminal diagnoses achieving long-term remission. BioOra Limited, a biotech firm partly owned by the Malaghan Institute of Medical Research, is spearheading the effort to scale up production for public and private healthcare systems.

BioOra is in the process of establishing a state-of-the-art manufacturing facility in Christchurch. The facility aims to efficiently produce CAR T-cell therapy using an automated system, minimizing contamination risks. Currently, patients seeking this life-saving treatment are often forced to pay exorbitant fees in countries like China. The anticipated facility will allow BioOra to manufacture the therapy at a lower cost, potentially making it accessible to many in need.

Managing Director John Robson expressed concerns about the pace of public health system approvals, stating, “We’re kind of on this knife edge of, will they go fast enough for us?” He believes that public access could be feasible by the first quarter of 2027, but this timeline hinges on securing necessary government funding. If the public system does not respond swiftly, the treatment may initially be offered privately, with discussions underway with interested providers.

Understanding CAR T-cell Therapy

CAR T-cell therapy represents a significant advancement in cancer treatment. The process involves collecting a patient’s immune cells, genetically modifying them to target and destroy cancer cells, and then reintroducing them into the patient’s bloodstream. While this therapy has become a standard treatment for certain blood cancers in Australia and other countries, it is not yet available in New Zealand.

The Malaghan Institute has developed its own version of CAR T-cell therapy, which has yielded promising results in a phase 1 clinical trial. The trial demonstrated that over half of the lymphoma patients, who had exhausted other treatment options and were critically ill, achieved remission within months. Moreover, the therapy exhibited significantly lower rates of severe side effects compared to available commercial options, suggesting it may be administered in outpatient settings, further reducing costs.

The second phase of the trial aims to finalize patient enrollment by October, with results expected to be submitted to Medsafe for approval thereafter. BioOra, a spin-out from the Malaghan Institute, is currently producing CAR T-cell therapy for clinical trials in Wellington while simultaneously raising funds to establish its new facility.

Future Prospects and Economic Considerations

The new Christchurch facility is designed to meet international good manufacturing practice (GMP) standards, ensuring the highest quality in drug production. Robson anticipates the site will be operational by late 2026, coinciding with the end of the clinical trials. The facility is projected to create approximately 45 to 50 jobs in the region.

The initial production capacity is set to treat 160 patients in the first year, with plans to expand to over 300 patients in the second year. Robson noted that while scaling production is crucial, it will also necessitate hiring and training new personnel.

Financially, the costs associated with CAR T-cell therapy are expected to be significantly lower than the average $1 million charged in countries like Australia and the United States. Robson emphasized that the economic benefits of providing this treatment could outweigh the initial investment, citing the potential for patients to return to work and contribute to society following successful treatment.

The funding landscape for public access remains uncertain. Robson highlighted that while the upfront costs are notable, the long-term savings from reduced hospital visits and interventions could be substantial. He stated, “If you have a 20 or 30-year-old that’s treated and they effectively go down this curative pathway, then their benefit and their input to New Zealand is huge.”

Efforts to secure funding are ongoing, with BioOra seeking governmental support to facilitate public access. The Ministry of Health, through the Cancer Control Agency, is leading discussions on the regulatory requirements for CAR T-cell therapy, with plans to introduce new legislation to streamline approval processes. Acting Chief Executive Nicola Hill indicated that the new Medical Products Bill would allow for flexible approval pathways, although full implementation may not be realized until late 2030.

As BioOra prepares for the future, it envisions not only serving the local market but also exploring opportunities in international markets, particularly in Australia. The company’s long-term goal is to become a leader in immunotherapy, with aspirations of attracting medical tourism. Such ambitions highlight the potential for New Zealand to become a key player in the global healthcare landscape.

The journey toward making CAR T-cell therapy widely available is fraught with challenges, but the progress made thus far is promising. As stakeholders continue to navigate regulatory and financial hurdles, the hope remains that this groundbreaking treatment will soon be accessible to those who need it most.